Prosecution Insights
Prosecution Insights
19 pending office actions • 11 art units • 19 examiners • 0 of 19 (0%) have an AI response strategy ready • 22 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (11%) |
| §103 only | 5 (26%) |
| Double-patenting only | 2 (11%) |
| Double-patenting + other | 6 (32%) |
| Multi-statute (no §101) | 4 (21%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSELEY II, NELSON B | 1 | 67.8% | +41.6% |
| BELYAVSKYI, MICHAIL A | 1 | 64.1% | +27.7% |
| PYLA, EVELYN Y | 1 | 55.7% | +47.6% |
| STONEBRAKER, ALYSSA RAE | 1 | 56.9% | +50.4% |
| JOHNSON, KARA D | 1 | 69.1% | +24.6% |
| HUYNH, EMILY | 1 | 21.6% | +43.4% |
| JUEDES, AMY E | 1 | 45.0% | +41.4% |
| CHASE, CAROL ANN | 1 | 44.1% | +84.3% |
| HUYNH, PHUONG N | 1 | 65.7% | +53.6% |
| KNIGHT, TERESA E | 1 | 65.7% | +48.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256853 | TREATMENT OF CANCERS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | CUNNINGCHEN, KATHLEEN MARY | 1d overdue |
| 18590860 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | HUYNH, EMILY | 16d |
| 18673083 | TREATMENT OF NSCLC PATIENTS REFRACTORY FOR ANTI-PD-1 ANTIBODY | STONEBRAKER, ALYSSA RAE | 55d |
| 18661510 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | JOHNSON, KARA D | — |
| 18548769 | TUMOR STORAGE AND CELL CULTURE COMPOSITIONS | KNIGHT, TERESA E | — |
| 18259644 | DEVICES AND PROCESSES FOR AUTOMATED PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES | HANDY, DWAYNE K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19011427 | TIL EXPANSION FROM FINE NEEDLE ASPIRATES AND SMALL BIOPSIES | MOSELEY II, NELSON B | 92d overdue |
| 18590860 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | HUYNH, EMILY | 16d |
| 18673083 | TREATMENT OF NSCLC PATIENTS REFRACTORY FOR ANTI-PD-1 ANTIBODY | STONEBRAKER, ALYSSA RAE | 55d |
| 18984525 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | BELYAVSKYI, MICHAIL A | — |
| 18745958 | PROCESSES FOR GENERATING TIL PRODUCTS ENRICHED FOR TUMOR ANTIGEN-SPECIFIC T-CELLS | PYLA, EVELYN Y | — |
| 18661510 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | JOHNSON, KARA D | — |
| 18429006 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) WITH TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (TNFRSF) AGONISTS AND THERAPEUTIC COMBINATIONS OF TILS AND TNFRSF AGONISTS | JUEDES, AMY E | — |
| 18560898 | PD-1 GENE-EDITED TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | CHASE, CAROL ANN | — |
| Art Unit | Apps |
|---|---|
| 1642 | 3 |
| 1644 | 2 |
| 1641 | 2 |
| 1638 | 2 |
| 3683 | 1 |
| 1634 | 1 |
| 1798 | 1 |
| 1646 | 1 |
| 1799 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19011427 | TIL EXPANSION FROM FINE NEEDLE ASPIRATES AND SMALL BIOPSIES | MOSELEY II, NELSON B | 1642 | §103 | Non-Final OA | 92d overdue | Pending | Jan 06, 2025 |
| 18984525 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | BELYAVSKYI, MICHAIL A | 1644 | §103 | Non-Final OA | — | Pending | Dec 17, 2024 |
| 18745958 | PROCESSES FOR GENERATING TIL PRODUCTS ENRICHED FOR TUMOR ANTIGEN-SPECIFIC T-CELLS | PYLA, EVELYN Y | — | §112DP | Non-Final OA | — | Pending | Jun 17, 2024 |
| 18673083 | TREATMENT OF NSCLC PATIENTS REFRACTORY FOR ANTI-PD-1 ANTIBODY | STONEBRAKER, ALYSSA RAE | 1642 | §103§112Other | Final Rejection | 55d | Pending | May 23, 2024 |
| 18661510 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | JOHNSON, KARA D | — | §101§102§103§112DP | Non-Final OA | — | Pending | May 10, 2024 |
| 18590860 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | HUYNH, EMILY | 3683 | §101§112 | Final Rejection | 16d | Pending | Feb 28, 2024 |
| 18429006 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) WITH TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (TNFRSF) AGONISTS AND THERAPEUTIC COMBINATIONS OF TILS AND TNFRSF AGONISTS | JUEDES, AMY E | 1644 | §102§103§112DP | Non-Final OA | — | Pending | Jan 31, 2024 |
| 18560898 | PD-1 GENE-EDITED TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | CHASE, CAROL ANN | — | DP | Non-Final OA | — | Pending | Nov 14, 2023 |
| 18551138 | METHODS FOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | HUYNH, PHUONG N | 1641 | DP | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18548769 | TUMOR STORAGE AND CELL CULTURE COMPOSITIONS | KNIGHT, TERESA E | 1634 | §102§103§112 | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18262843 | ADJUVANT THERAPY FOR CANCER | WEN, SHARON X | 1641 | §103DP | Final Rejection | 20d | Pending | Jul 25, 2023 |
| 18259644 | DEVICES AND PROCESSES FOR AUTOMATED PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES | HANDY, DWAYNE K | 1798 | §102§103§112 | Non-Final OA | — | Pending | Jun 28, 2023 |
| 18256853 | TREATMENT OF CANCERS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | CUNNINGCHEN, KATHLEEN MARY | 1646 | §102§103§112Other | Non-Final OA | 1d overdue | Pending | Jun 09, 2023 |
| 18249380 | CELL CULTURE SYSTEM AND METHODS OF USING THE SAME | HURST, JONATHAN M | 1799 | §103 | Non-Final OA | — | Pending | Apr 17, 2023 |
| 18247878 | TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | AEDER, SEAN E | 1642 | §103Other | Non-Final OA | — | Pending | Apr 04, 2023 |
| 17829087 | RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES | KELLY, ROBERT M | 1638 | §112DP | Non-Final OA | 23d | Pending | May 31, 2022 |
| 17771723 | GENE EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | BERTOGLIO, VALARIE E | 1632 | §103DPOther | Non-Final OA | 5d overdue | Pending | Apr 25, 2022 |
| 17267699 | Expansion of TILs from Cryopreserved Tumor Samples | O'NEILL, MARISOL ANN | 1633 | §103 | Final Rejection | 12d | Pending | Jan 10, 2022 |
| 17610671 | METHODS AND COMPOSITIONS FOR SELECTING TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY | AMICK, THOMAS RUSSE | 1638 | §103DPOther | Non-Final OA | 70d | Pending | Nov 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial